Growth Hormone Secretagogues

Pituitary growth hormone output declines with age - roughly ten percent per decade after the mid-thirties by most estimates. The consequences are not cosmetic: sleep architecture flattens, recovery slows, connective tissue thins and body composition shifts toward fat. Growth hormone secretagogues are studied as a way to prompt the pituitary to release more of its own hormone rather than supplying it from outside.

Direct somatropin raises circulating GH regardless of what the pituitary is doing. A secretagogue depends on pituitary function, so the response is proportional to what the gland can still produce. In a younger body the pulse is larger; with age it shrinks.

That is both the limitation and the appeal. The route preserves the body's own feedback and pulsatility, which is closer to normal physiology than a continuous exogenous level. It is also gentler on insulin sensitivity than high-dose somatropin, because the total exposure is lower.

The Compounds

Ipamorelin is a selective ghrelin-receptor agonist that produces a clean pulse without meaningful cortisol or prolactin elevation. It is the most commonly used secretagogue in longevity-oriented protocols because its side-effect profile is narrow.

CJC-1295 is a GHRH analogue. The DAC form binds albumin and extends the half-life substantially, which allows less frequent dosing. Sermorelin is the shorter GHRH analogue and produces a more physiological pulse.

GHRP-2 and GHRP-6 are older ghrelin mimetics with broader receptor activity. GHRP-6 raises appetite noticeably; both can raise cortisol and prolactin at higher doses.

Direct Somatropin and IGF-1 LR3

Somatropin remains the reference compound. It has the largest evidence base for body composition, bone density and connective tissue, and it is also the most expensive and the most demanding on glucose metabolism.

IGF-1 LR3 is a long-acting IGF-1 analogue that bypasses the pituitary entirely. It is studied for cell growth and repair, and it carries its own risk profile, including effects on glucose handling.

Realistic Timelines

Sleep depth and recovery often change within two to three weeks. Body composition and skin quality take around three months of consistent use. Bone and connective-tissue endpoints are measured over much longer periods.

Anyone promising reversal of ageing inside a month is not describing pharmacology. The measurable endpoints in this category are tissue quality and metabolic markers, not lifespan.

Monitoring

IGF-1 is the standard marker for GH exposure, and fasting glucose and insulin sensitivity are the markers that matter most for safety. Baseline bloodwork and a follow-up panel are the minimum for any protocol lasting longer than a few weeks.

Because secretagogues depend on pituitary response, IGF-1 also tells you whether the dose is doing anything at all.

Handling and Storage

Lyophilised peptides ship stable and are reconstituted with bacteriostatic water. Store the solution at 2-8°C, protected from light, and avoid freeze-thaw cycles. Somatropin requires cold storage in both powder and pen formats.

Listings state vial size or pen strength and live stock. This page covers the ageing rationale and monitoring; the product page carries the full specification and buying details.